Clinical trials: Hepatitis C Infections
Hepatitis C, Chronic, Hepatitis C
Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)
In patients with chronic hepatitis C, the ultimate treatment goal is the improvement of liver histology and inhibition of progression to liver cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT00787371
- Testing
- PegIntron (peginterferon alfa-2b)
- Volunteers
- 69 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus (HCV)
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.
- Trial name
- NCT03341871
- Where
- Japan
- Volunteers
- 1,095 people
- Sponsor
- AbbVie
HIV Infections, Hepatitis C
Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
A study concerning viral kinetic with 10 co-infected HIV-HCV patients on treatment with peginterferon alfa-2a + ribavirin o IFN + ribavirin was reported in Conference on Retroviruses and Opportunistic Infections 2002 by Dr.
- Trial name
- NCT00612755
- Testing
- Peginterferon alfa-2a + ribavirin
- Where
- 19 sites in Spain
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Hospital Clinico Universitario San Cecilio
Hepatitis C, Fibrosis
The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital
The primary objective is to assess the prevalence and genotypes of HCV infection in thalassemia major and thalassemia intermediate patients who have received blood transfusion in the Department of Medicine, Faculty of Medicine…
- Conditions
- Hepatitis C, Fibrosis, Thalassemia
- Trial name
- NCT02904252
- Testing
- Transient elastography
- Where
- Thailand
- Volunteers
- 158 people
- Sponsor
- Mahidol University
Hepatitis C
Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.
- Trial name
- NCT00239252
- Testing
- Interferon alfacon-1
- Where
- 5 sites in Japan
- Sponsor
- Astellas Pharma Inc
Hepatitis C
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
This is a two-part study of grazoprevir (MK-5172) + elbasvir (MK-8742) in Japanese participants with chronic hepatitis C virus (HCV) genotype 1 (GT1).
- Trial name
- NCT02203149
- Testing
- Grazoprevir, Elbasvir
- Volunteers
- 399 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Liver Diseases
Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
The purpose of this study is to validate the first round HCV early dynamics discovery within a larger population.
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Interferon Deficiency
- Trial name
- sIFN-pred2 (NCT01760148)
- Testing
- interferon alpha 2b
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Junqi Niu
HCV Infection
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and activity of escalating, multiple, oral doses of GS-5885 in subjects with chronic genotype 1 Hepatitis C Virus (HCV) infection.
- Trial name
- NCT01193478
- Testing
- GS-5885
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gilead Sciences
Hepatitis C Viral, Chronic Kidney Disease stage3
A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
The regimen using grazoprevir plus elbasvir treatment is promising in Japan, because it may safely be used for the elderly patients with renal dysfunction.
- Trial name
- NCT03144635
- Testing
- Grazoprevir plus Elbasvir
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Kyushu University
Chronic Hepatitis C
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
Aim of the present study is to evaluate in a cohort of patients with genotype 2/3 chronic hepatitis C, relapsers to a previous PEG-IFN + ribavirin therapy (alpha-2a or alpha-2b) the efficacy of PEG-IFNα-2a + ribavirin…
- Trial name
- NCT01517308
- Testing
- pegylated interferon alpha 2a + ribavirin
- Where
- Italy
- Sponsor
- Federico II University
Hepatitis C, Hiv
Zepatier in Patients with Substance Use
The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or…
- Conditions
- Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
- Trial name
- NCT04048850
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Illinois Chicago
Hepatitis C, Cirrhosis
Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis
Direct-acting antiviral agents (DAAs) targeting HCV have revolutionized the treatment of HCV. The efficacy of DAA-based therapy can depend on patient-related factors such as treatment experience, cirrhosis, but also on viral…
- Trial name
- NCT05467826
- Testing
- Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Hepatitis C, Chronic
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This prospective observational study will assess the insulin resistance and its impact on sustained virological response in patients with hepatitis C treated with Pegasys and Copegus.
- Trial name
- NCT01200225
- Where
- France
- Volunteers
- 1,155 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Occult HCV Infection After DAAD Treatment in Haemodialysis Patients
This research aims to evaluate the prevalence and predictors of Occult HCV among hemodialysis (HD) patients who achieved 24 weeks sustained virological response (SVR) after treatment with direct-acting antiviral agents (DAA) by…
- Trial name
- NCT04719338
- Testing
- presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Alexandria University
Chronic Hepatitis c
Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model
Background and Aims: The prevalence of hepatitis C virus infection (HCV) infection in Punjab, India is 3.29%, with an estimated burden of around 650,000 viremic chronic HCV (CHC) patients.
- Trial name
- NCT03488485
- Testing
- Direct Acting Antivirals
- Where
- India
- Volunteers
- 50,000 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatitis C
A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
This multiple dose study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)- infected participants.
- Trial name
- NCT00998985
- Testing
- Grazoprevir
- Volunteers
- 91 people
- Sponsor
- Merck Sharp & Dohme LLC
HCV Infection
Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.
- Trial name
- NCT00696904
- Testing
- ABT-333
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- AbbVie
HIV Infections, Hepatitis C
Zidovudine Levels in HIV Infected Patients Being Treated for HCV
This study will test the amount of anti-HIV drugs in the blood cells of HIV-infected patients who are also being treated for hepatitis C virus (HCV) infection.
- Trial name
- NCT00059358
- Testing
- Ribavirin plus interferon alfa-2b, Ribavirin, Peginterferon alfa-2b
- Where
- Puerto Rico
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Indolent Lymphoma
Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma
We and other investigators have revealed an association between Hepatitis C virus (HCV) seropositivity and an increased risk of developing marginal zone B-cell lymphoma (MZ), lymphoplasmacytic lymphoma (LPL, also known as…
- Trial name
- NCT03261349
- Testing
- Ledipasvir and sofosbuvir
- Volunteers
- 21 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C, HIV Infections
Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV
The purpose of this study is to measure the effects of anti-HIV drugs on hepatitis C virus (HCV) viral load in people infected with both HCV and HIV.
- Trial name
- ART and HCV (NCT00545558)
- Testing
- Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.